RANKL signaling has been one of the important factors in the proliferation and multiplication of osteosarcoma [175] leading to the investigation of Denosumab a complete human monoclonal antibody against RANKL which has showed promising results for giant cell tumor of bone(GCTB). This evidence concerns the gene TNFSF11 and bone giant cell tumor.